Angiogenesis in endocrine tumors.

Angiogenesis is the process of new blood vessel development from preexisting vasculature. Although vascular endothelium is usually quiescent in the adult, active angiogenesis has been shown to be an important process for new vessel formation, tumor growth, progression, and spread. The angiogenic phenotype depends on the balance of proangiogenic growth factors such as vascular endothelial growth factor (VEGF) and inhibitors, as well as interactions with the extracellular matrix, allowing for endothelial migration. Endocrine glands are typically vascular organs, and their blood supply is essential for normal function and tight control of hormone feedback loops. In addition to metabolic factors such as hypoxia, the process of angiogenesis is also regulated by hormonal changes such as increased estrogen, IGF-I, and TSH levels. By measuring microvascular density, differences in angiogenesis have been related to differences in tumor behavior, and similar techniques have been applied to both benign and malignant endocrine tumors with the aim of identification of tumors that subsequently behave in an aggressive fashion. In contrast to other tumor types, pituitary tumors are less vascular than normal pituitary tissue, although the mechanism for this observation is not known. A relationship between angiogenesis and tumor size, tumor invasiveness, and aggressiveness has been shown in some pituitary tumor types, but not in others. There are few reports on the role of microvascular density or angiogenic factors in adrenal tumors. The mechanism of the vascular tumors, which include adrenomedullary tumors, found in patients with Von Hippel Lindau disease has been well characterized, and clinical trials of antiangiogenic therapy are currently being performed in patients with Von Hippel Lindau disease. Thyroid tumors are more vascular than normal thyroid tissue, and there is a clear correlation between increased VEGF expression and more aggressive thyroid tumor behavior and metastasis. Although parathyroid tissue induces angiogenesis when autotransplanted and PTH regulates both VEGF and MMP expression, there are few studies of angiogenesis and angiogenic factors in parathyroid tumors. An understanding of the balance of angiogenesis in these vascular tumors and mechanisms of vascular control may assist in therapeutic decisions and allow appropriately targeted treatment.

[1]  R. Muschel,et al.  Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. , 1996, Cancer research.

[2]  J. Folkman,et al.  Tumor angiogenesis: iris neovascularization at a distance from experimental intraocular tumors. , 1973, Journal of the National Cancer Institute.

[3]  P. Comoglio,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Negative/Low Expression of the Met/Hepatocyte Growth Factor Receptor Identifies Papillary Thyroid , 2022 .

[4]  S. Melmed,et al.  Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis , 1999, Nature Medicine.

[5]  P. Colville-Nash,et al.  Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications. , 1992, Annals of the rheumatic diseases.

[6]  M. Dewhirst,et al.  Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[7]  G. Popa,et al.  THE VASCULAR LINK BETWEEN THE PITUITARY AND THE HYPOTHALAMUS. , 1930 .

[8]  G. Chiesa,et al.  Liposome-delivered angiostatin strongly inhibits tumor growth and metastatization in a transgenic model of spontaneous breast cancer. , 2000, Cancer research.

[9]  T. Nakajima,et al.  c‐Met expression of thyroid tissue with special reference to papillary carcinoma , 1998, Pathology international.

[10]  J. Folkman Editorial: Is Tissue Mass Regulated by Vascular Endothelial Cells? Prostate as the First Evidence. , 1998, Endocrinology.

[11]  A. Buckley,et al.  Proteolysis of Human Prolactin: Resistance to Cathepsin D and Formation of a Nonangiostatic, C-Terminal 16K Fragment by Thrombin1. , 1999, Endocrinology.

[12]  M. Puzianowska-Kuźnicka,et al.  Differential regulation of three thyroid hormone‐responsive matrix metalloproteinase genes implicates distinct functions during frog embryogenesis , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  J. Martial,et al.  16K human prolactin inhibits vascular endothelial growth factor-induced activation of Ras in capillary endothelial cells. , 1999, Molecular endocrinology.

[14]  C. Larsson,et al.  Differential loss of heterozygosity in familial, sporadic, and uremic hyperparathyroidism , 1997, Human Genetics.

[15]  D. Hill,et al.  Changes in the immunohistochemical localisation of fibroblast growth factor-2, transforming growth factor-beta 1 and thrombospondin-1 are associated with early angiogenic events in the hyperplastic rat thyroid. , 1996, The Journal of endocrinology.

[16]  Machein,et al.  Differential downregulation of vascular endothelial growth factor by dexamethasone in normoxic and hypoxic rat glioma cells , 1999, Neuropathology and applied neurobiology.

[17]  P. Comoglio,et al.  Expression of Met protein and urokinase‐type plasminogen activator receptor (uPA‐R) in papillary carcinoma of the thyroid , 1998, The Journal of pathology.

[18]  J. Schechter,et al.  Morphological evidence for the presence of arteries in human prolactinomas. , 1988, The Journal of clinical endocrinology and metabolism.

[19]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[20]  J. Martial,et al.  Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[22]  C. Martínez-A,et al.  The Matrix Metalloproteinase-9 Regulates the Insulin-like Growth Factor-triggered Autocrine Response in DU-145 Carcinoma Cells* , 1999, The Journal of Biological Chemistry.

[23]  K. Matsumoto,et al.  Identification and characterization of high molecular weight forms of basic fibroblast growth factor in human pituitary adenomas. , 1992, The Journal of clinical endocrinology and metabolism.

[24]  O. Melnyk,et al.  Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. , 1999, The Journal of urology.

[25]  T. Kawamoto,et al.  Effects of parathyroid hormone (PTH) and PTH-related peptide on expressions of matrix metalloproteinase-2, -3, and -9 in growth plate chondrocyte cultures. , 1998, Endocrinology.

[26]  P. Porter,et al.  Thrombospondin-1, an inhibitor of angiogenesis, is regulated by progesterone in the human endometrium. , 1996, The Journal of clinical investigation.

[27]  Y. Sinha,et al.  Cleaved prolactin: evidence for its occurrence in human pituitary gland and plasma. , 1985, The Journal of clinical endocrinology and metabolism.

[28]  J. Franklyn,et al.  Expression of fibroblast growth factors in thyroid cancer. , 1995, The Journal of clinical endocrinology and metabolism.

[29]  H. Augustin Angiogenesis in the female reproductive system. , 2005, EXS.

[30]  E Medico,et al.  Met overexpression confers HGF‐dependent invasive phenotype to human thyroid carcinoma cells in vitro , 1999, Journal of cellular physiology.

[31]  J. Wass,et al.  Pituitary, adrenal and thyroid incidentalomas , 1998 .

[32]  J. Donckier,et al.  Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. , 1997, The Journal of clinical endocrinology and metabolism.

[33]  A. Logan,et al.  Basic fibroblast growth factor affects DNA synthesis and cell function and activates multiple signalling pathways in rat thyroid FRTL-5 and pituitary GH3 cells. , 1990, The Journal of endocrinology.

[34]  G. Conway,et al.  Serum vascular endothelial growth factor concentrations in postmenopausal women: the effect of hormone replacement therapy. , 2000, Fertility and sterility.

[35]  P. Maher,et al.  Inhibition of Cell Migration and Angiogenesis by the Amino-terminal Fragment of 24kD Basic Fibroblast Growth Factor* , 2002, The Journal of Biological Chemistry.

[36]  J. Folkman,et al.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.

[37]  J. Arbiser,et al.  Corticotropin-releasing hormone stimulates angiogenesis and epithelial tumor growth in the skin. , 1999, The Journal of investigative dermatology.

[38]  D. Basile,et al.  Basic fibroblast growth factor may mediate proliferation in the compensatory adrenal growth response. , 1993, The American journal of physiology.

[39]  M. Welsh,et al.  Effects of vascular endothelial growth factor on pancreatic duct cell replication and the insulin production of fetal islet-like cell clusters in vitro , 1997, Molecular and Cellular Endocrinology.

[40]  B. Shilo,et al.  Insulin induces transcription of target genes through the hypoxia‐inducible factor HIF‐1α/ARNT , 1998, The EMBO journal.

[41]  P. Marc,et al.  Human growth hormone stimulates proteinase activities of rabbit bone cells via IGF-I. , 2000, Biochemical and biophysical research communications.

[42]  D. Sarkar,et al.  Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis. , 1997, Carcinogenesis.

[43]  H. Fraser,et al.  Inhibition of early luteal angiogenesis by gonadotropin-releasing hormone antagonist treatment in the primate. , 2000, The Journal of clinical endocrinology and metabolism.

[44]  J. Slodkowska,et al.  Lung carcinoids. Tumor angiogenesis in relation to clinicopathologic characteristics. , 1999, Analytical and quantitative cytology and histology.

[45]  A. Harris von Hippel-Lindau syndrome: target for anti-vascular endothelial growth factor (VEGF) receptor therapy. , 2000, The oncologist.

[46]  A. Harris,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society Role of Matrix Metalloproteinase 9 in Pituitary Tumor Behavior , 2000 .

[47]  K. Alitalo,et al.  Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[48]  G. Viglietto,et al.  Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene , 1999, Oncogene.

[49]  G. Giannattasio,et al.  Microvasculature of human micro- and macroprolactinomas. A morphological study. , 1986, Neuroendocrinology.

[50]  S. Brem,et al.  Angiogenesis as a marker of preneoplastic lesions of the human breast , 1978, Cancer.

[51]  K. Plate,et al.  Vascular endothelial growth factor , 1997, Journal of Neuro-Oncology.

[52]  E. Woltering,et al.  Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent. , 1993, The Journal of surgical research.

[53]  J. Stanfield,et al.  The blood supply of the human pituitary gland. , 1960, Journal of anatomy.

[54]  M. Bar,et al.  Sporadic phaeochromocytomas are rarely associated with germline mutations in the von Hippel‐Lindau and RET genes , 1997, Clinical endocrinology.

[55]  D. King,et al.  Mass spectrometric analysis of the fragments produced by cleavage and reduction of rat prolactin: evidence that the cleaving enzyme is cathepsin D. , 1993, Endocrinology.

[56]  L. Ericson,et al.  Blood capillary enlargement during the development of thyroid hyperplasia in the rat. , 1978, Endocrinology.

[57]  D. Edwards,et al.  THE MATRIX METALLOPROTEINASES AND THEIR INHIBITORS , 2005 .

[58]  M. Hoshino,et al.  Inhaled corticosteroids decrease subepithelial collagen deposition by modulation of the balance between matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in asthma. , 1999, The Journal of allergy and clinical immunology.

[59]  A. Ullrich,et al.  Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant , 1994, Nature.

[60]  J. Amano,et al.  Expression of fibroblast growth factor-2 and fibroblast growth factor receptor-1 in thyroid diseases: difference between neoplasms and hyperplastic lesions. , 1998, Endocrine journal.

[61]  M. Ivan,et al.  Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells , 1997, Oncogene.

[62]  L. Bresler*,et al.  Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. , 1999, The Journal of endocrinology.

[63]  A. Kulig,et al.  Inhibitory effects of fumagillin and its analogue TNP-470 on the function, morphology and angiogenesis of an oestrogen-induced prolactinoma in Fischer 344 rats. , 1996, The Journal of endocrinology.

[64]  M. McCarthy,et al.  Localisation of a gene causing endocrine neoplasia to a 4 cM region on chromosome 1p35-p36. , 1997, Journal of medical genetics.

[65]  Erwin G. Van Meir,et al.  Thrombospondins and tumor angiogenesis. , 2001, Trends in molecular medicine.

[66]  W. Fantl,et al.  Signalling by receptor tyrosine kinases. , 1993, Annual review of biochemistry.

[67]  S. Leung,et al.  Vascular endothelial growth factor is up‐regulated in the early pre‐malignant stage of colorectal tumour progression , 1999, International journal of cancer.

[68]  B. Bussolati,et al.  Angiopoietin-1 and angiopoietin-2 activate trophoblast Tie-2 to promote growth and migration during placental development. , 2000, The American journal of pathology.

[69]  D. Hill,et al.  Presence and possible role of vascular endothelial growth factor in thyroid cell growth and function. , 1998, The Journal of endocrinology.

[70]  R. Warren,et al.  Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. , 1995, The Journal of clinical investigation.

[71]  Stanfield Jp The blood supply of the human pituitary gland. , 1960 .

[72]  G. Viglietto,et al.  Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization , 1997, Oncogene.

[73]  Thomas Hawighorst,et al.  Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis , 2001, Nature Medicine.

[74]  U. Pagotto,et al.  Pituitary adenylate cyclase-activating polypeptide, interleukin-6 and glucocorticoids regulate the release of vascular endothelial growth factor in pituitary folliculostellate cells. , 1999, The Journal of endocrinology.

[75]  K. Seibert,et al.  COX‐2 Inhibitors: A New Class of Antiangiogenic Agents , 1999, Annals of the New York Academy of Sciences.

[76]  N. Iwahori,et al.  Parathyroid hormone-related peptide is a potent tumor angiogenic factor. , 2000, Endocrinology.

[77]  T. Dwight,et al.  Loss of heterozygosity in sporadic parathyroid tumours: involvement of chromosome 1 and the MEN1 gene locus in 11q13. , 2000, Clinical endocrinology.

[78]  S. Gruber,et al.  Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[79]  E. Van Obberghen,et al.  Insulin and Insulin-like Growth Factor-I Induce Vascular Endothelial Growth Factor mRNA Expression via Different Signaling Pathways* , 2000, The Journal of Biological Chemistry.

[80]  L. Aiello,et al.  Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[81]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[82]  Q. Duh,et al.  Thyroid-stimulating hormone promotes the secretion of vascular endothelial growth factor in thyroid cancer cell lines. , 1996, Surgery.

[83]  E. Manseau,et al.  Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. , 1993, Cancer research.

[84]  G. Semenza,et al.  Structural and functional analysis of hypoxia-inducible factor 1. , 1997, Kidney international.

[85]  J. Smit,et al.  Degradation of extracellular matrix by metastatic follicular thyroid carcinoma cell lines: role of the plasmin activation system. , 1999, Thyroid : official journal of the American Thyroid Association.

[86]  E. Scanziani,et al.  Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[87]  G. Maira,et al.  Immunohistochemical detection of folliculo-stellate cells in human pituitary adenomas , 1984, Virchows Archiv. B, Cell pathology including molecular pathology.

[88]  M. Witt,et al.  Galactose and fucose binding sites in anterior pituitary cells of the rat. Detection by means of biotinylated lectins. , 1987, Folia histochemica et cytobiologica.

[89]  R. Mitchell,et al.  Pituitary follicular cells produce basic fibroblast growth factor. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[90]  R. Morris,et al.  Vascular endothelial growth factor in the rat pituitary: differential distribution and regulation by estrogen. , 2000, The Journal of endocrinology.

[91]  M. Neeman,et al.  The antiangiogenic agent linomide inhibits the growth rate of von Hippel-Lindau paraganglioma xenografts to mice. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[92]  Georg Breier,et al.  Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.

[93]  J. Schechter,et al.  Estrogen-induced tumors: changes in the vasculature in two strains of rat. , 1987, The American journal of anatomy.

[94]  L. Ellis,et al.  Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. , 1998, Cancer research.

[95]  T. Saclarides,et al.  Tumor angiogenesis in pheochromocytomas and paragangliomas. , 1996, Surgery.

[96]  Y. Sinha,et al.  A cleaved form of prolactin in the mouse pituitary gland: identification and comparison of in vitro synthesis and release in strains with high and low incidences of mammary tumors. , 1984, Endocrinology.

[97]  J. Pickard,et al.  Hyperprolactinemia, intrasellar pituitary tissue pressure, and the pituitary stalk compression syndrome. , 1987, Journal of neurosurgery.

[98]  M. Kirschner,et al.  Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. , 1999, Science.

[99]  L. Portugal,et al.  Well‐differentiated thyroid carcinomas: p53 mutation status and microvessel density , 1998, Head & neck.

[100]  R. Klausner,et al.  Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[101]  L. Liotta,et al.  Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. , 1989, The Journal of biological chemistry.

[102]  Saxe Aw Angiogenesis of human parathyroid tissue. , 1984 .

[103]  R. Weyant,et al.  Prognostic markers in pheochromocytoma. , 1998, Human pathology.

[104]  B. C. Patterson,et al.  Angiostatin-converting Enzyme Activities of Human Matrilysin (MMP-7) and Gelatinase B/Type IV Collagenase (MMP-9)* , 1997, The Journal of Biological Chemistry.

[105]  B. Coulombe,et al.  Decreased expression of tissue inhibitor of metalloproteinases in metastatic tumor cells leading to increased levels of collagenase activity. , 1991, Cancer research.

[106]  Reduced retinal vascularization in children with growth hormone deficiency. , 1999, The Journal of clinical endocrinology and metabolism.

[107]  M. Pawlikowski,et al.  Immunocytochemical investigations on the vascularization of pituitary adenomas , 1997, Endocrine pathology.

[108]  P. Rao,et al.  Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. , 1998, British Journal of Cancer.

[109]  E. Manseau,et al.  Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. , 1993, The American journal of pathology.

[110]  Q. Duh,et al.  Phenylacetate inhibits growth and vascular endothelial growth factor secretion in human thyroid carcinoma cells and modulates their differentiated function. , 1999, The Journal of clinical endocrinology and metabolism.

[111]  R K Jain,et al.  Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[112]  C. Jackson,et al.  Human microvascular endothelial cells differ from macrovascular endothelial cells in their expression of matrix metalloproteinases. , 1997, The international journal of biochemistry & cell biology.

[113]  A. Douglas-Jones,et al.  Epidermal Growth Factor Receptor Status in Hyperparathyroidism: Immunocytochemical and In Situ Hybridization Study , 1996, World Journal of Surgery.

[114]  L. Akslen,et al.  Increased angiogenesis in papillary thyroid carcinoma but lack of prognostic importance. , 2000, Human pathology.

[115]  C. Patterson,et al.  Induction of Vascular Endothelial Growth Factor Gene Expression by Interleukin-1 in Rat Aortic Smooth Muscle Cells (*) , 1995, The Journal of Biological Chemistry.

[116]  S. Mori,et al.  Colocalization of vascular endothelial growth factor (vascular permeability factor) and insulin in pancreatic islet cells. , 1995, The Journal of clinical endocrinology and metabolism.

[117]  M. Neeman,et al.  Loss of ovarian function promotes angiogenesis in human ovarian carcinoma. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[118]  P. Opolon,et al.  Combined effects of radiotherapy and angiostatin gene therapy in glioma tumor model. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[119]  M. Takigawa,et al.  Induction of angiogenesis in chick yolk-sac membrane by polyamines and its inhibition by tissue inhibitors of metalloproteinases (TIMP and TIMP-2). , 1990, Biochemical and biophysical research communications.

[120]  M. Shibuya,et al.  Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[121]  M. Toi,et al.  Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression , 2004, Breast Cancer Research and Treatment.

[122]  M. Iitaka,et al.  Increased serum vascular endothelial growth factor levels and intrathyroidal vascular area in patients with Graves' disease and Hashimoto's thyroiditis. , 1998, The Journal of clinical endocrinology and metabolism.

[123]  D. Talbot,et al.  Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. , 1996, European journal of cancer.

[124]  R. Weiner,et al.  Direct arterial vascularization of estrogen-induced prolactin-secreting anterior pituitary tumors. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[125]  C. Clapp,et al.  A 14-kilodalton prolactin-like fragment is secreted by the hypothalamo-neurohypophyseal system of the rat. , 1995, Endocrinology.

[126]  F. Basolo,et al.  Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995). , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[127]  W. Scherbaum,et al.  Human thyroid carcinoma cell lines and normal thyrocytes: expression and regulation of matrix metalloproteinase-1 and tissue matrix metalloproteinase inhibitor-1 messenger-RNA and protein. , 1997, Thyroid : official journal of the American Thyroid Association.

[128]  A. Harris,et al.  Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer , 1992, The Lancet.

[129]  Anthony J. Guidi,et al.  Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. , 1995, Human pathology.

[130]  H. Augustin,et al.  Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[131]  J. Folkman,et al.  Angiostatin induces and sustains dormancy of human primary tumors in mice , 1996, Nature Medicine.

[132]  W. Kaelin,et al.  Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. , 1999, Science.

[133]  H. Drexhage,et al.  Morphological, immunohistochemical and functional homologies between pituitary folliculo-stellate cells and lymphoid dendritic cells. , 1991, Acta Endocrinologica.

[134]  A. Genazzani,et al.  Correlation between the amount of follicle-stimulating hormone administered and plasma and follicular fluid vascular endothelial growth factor concentrations in women undergoing in vitro fertilization. , 1998, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[135]  K. Kurisu,et al.  Inhibitory effect of TNP-470, a new anti-angiogenic agent, on the estrogen induced rat pituitary tumors. , 1994, Anticancer research.

[136]  C. Patterson,et al.  Enhanced expression of vascular endothelial growth factor in human SaOS-2 osteoblast-like cells and murine osteoblasts induced by insulin-like growth factor I. , 1996, Endocrinology.

[137]  S. Groshen,et al.  Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. , 1995, Journal of the National Cancer Institute.

[138]  M. Bednarski,et al.  Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. , 1998, Nature medicine.

[139]  K. Smith-McCune,et al.  Demonstration and characterization of the angiogenic properties of cervical dysplasia. , 1994, Cancer research.

[140]  A. Harris,et al.  Proliferation, bcl-2 expression and angiogenesis in pituitary adenomas: relationship to tumour behaviour , 2000, British Journal of Cancer.

[141]  K. Arita,et al.  Type IV collagenase activity and cavernous sinus invasion in human pituitary adenomas , 2005, Acta Neurochirurgica.

[142]  N. Ferrara,et al.  The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.

[143]  D. Mooney,et al.  Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. , 1999, The American journal of pathology.

[144]  K. Alitalo,et al.  Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. , 1994, The Journal of biological chemistry.

[145]  U. Renner,et al.  High levels of matrix metalloproteinases regulate proliferation and hormone secretion in pituitary cells. , 2000, The Journal of clinical endocrinology and metabolism.

[146]  M. Brandi,et al.  Proliferation of endothelial component of parathyroid gland in multiple endocrine neoplasia type 1. Potential relationship with a mitogenic factor. , 1993, The American journal of pathology.

[147]  C. Heldin,et al.  Expression of transforming growth factors beta 1, beta 2, beta 3 in neuroendocrine tumors of the digestive system. , 1994, Anticancer research.

[148]  J. Folkman Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. , 1995, The New England journal of medicine.

[149]  J. Winer,et al.  Pituitary follicular cells secrete an inhibitor of aortic endothelial cell growth: identification as leukemia inhibitory factor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[150]  D. Marmé,et al.  Expression of the vascular endothelial growth factor gene is inhibited by p73 , 2000, Oncogene.

[151]  P. Sears,et al.  Biological and immunological characterization of cleaved and 16K forms of rat prolactin. , 1988, Endocrinology.

[152]  J. Schechter,et al.  Activation of anterior pituitary folliculo-stellate cells in the formation of estrogen-induced prolactin-secreting tumors. , 1988, Neuroendocrinology.

[153]  A. Harris,et al.  Angiogenesis in pituitary adenomas and the normal pituitary gland. , 2000, The Journal of clinical endocrinology and metabolism.

[154]  H M Jensen,et al.  Angiogenesis induced by "normal" human breast tissue: a probable marker for precancer. , 1982, Science.

[155]  Meijia Yang,et al.  Angioarrestin: an antiangiogenic protein with tumor-inhibiting properties. , 2002, Cancer research.

[156]  Claudio Eccher,et al.  Microvessel density quantification in breast carcinomas. Assessment by light microscopy vs. a computer-aided image analysis system , 1995 .

[157]  R. Weiner,et al.  Formation of a direct arterial blood supply to the anterior pituitary gland following complete or partial interruption of the hypophyseal portal vessels. , 1984, Neuroendocrinology.

[158]  H. Greene HETEROLOGOUS TRANSPLANTATION OF MAMMALIAN TUMORS I. THE TRANSFER OF RABBIT TUMORS TO ALIEN SPECIES , 1941 .

[159]  J. Martial,et al.  Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[160]  D. Hanahan,et al.  Induction of angiogenesis during the transition from hyperplasia to neoplasia , 1989, Nature.

[161]  R. Xavier,et al.  Tumor Induction of VEGF Promoter Activity in Stromal Cells , 1998, Cell.

[162]  P. Dandona,et al.  Stable over-expression of estrogen receptor-α in ECV304 cells inhibits proliferation and levels of secreted endothelin-1 and vascular endothelial growth factor , 1999, Molecular and Cellular Endocrinology.

[163]  R. D'Amato,et al.  Regulation of Vascular Endothelial Growth Factor Expression by Insulin-Like Growth Factor I , 1997, Diabetes.

[164]  J. Foekens,et al.  Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene. , 1999, Cancer research.

[165]  D. Hanahan,et al.  Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. , 1999, Science.

[166]  W. Jeffcoate,et al.  Long‐term follow‐up of patients with hyperprolactinaemia , 1996, Clinical endocrinology.

[167]  Marcel Karperien,et al.  Printed in U.S.A. Copyright © 2000 by The Endocrine Society Expression of Vascular Endothelial Growth Factors and Their Receptors during Osteoblast Differentiation , 2022 .

[168]  K. Alitalo,et al.  Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[169]  A. Gazdar,et al.  Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[170]  B. Scheithauer,et al.  Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas , 1999, Endocrine pathology.

[171]  R. Bergland,et al.  Pituitary-brain vascular relations: a new paradigm. , 1979, Science.

[172]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[173]  K. W. Kim,et al.  Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. , 1998, Cancer research.

[174]  L. Formigli,et al.  HPE cells: a clonal endothelial cell line established from human parathyroid tissue (human parathyroid cell line). , 1997, Endothelium : journal of endothelial cell research.

[175]  J. Schechter Ultrastructural changes in the capillary bed of human pituitary tumors. , 1972, The American journal of pathology.

[176]  I. B. Borel Rinkes,et al.  Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy. , 2000, Cancer research.

[177]  K. Alitalo,et al.  Vascular endothelial growth factor B, a novel growth factor for endothelial cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[178]  E. Woltering,et al.  Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane. , 1991, The Journal of surgical research.

[179]  N. Weidner,et al.  Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma. , 1994, The American journal of pathology.

[180]  H. Namba,et al.  Expression of parathyroid hormone related peptide in human pituitary tumours. , 1993, Journal of clinical pathology.

[181]  J. Folkman,et al.  Anti‐Angiogenesis: New Concept for Therapy of Solid Tumors , 1972, Annals of surgery.

[182]  D. Gomez,et al.  Ras oncogene mediated induction of a 92 kDa metalloproteinase; strong correlation with the malignant phenotype. , 1988, Biochemical and biophysical research communications.

[183]  P. Maxwell Oxygen homeostasis and cancer: insights from a rare disease. , 2002, Clinical medicine.

[184]  M. Farquhar,et al.  ELECTRON MICROSCOPIC STUDIES OF THE ANTERIOR PITUITARY GLAND , 1953, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[185]  L. Jin,et al.  Expression of D-type cyclins in normal and neoplastic rat pituitary. , 1998, Endocrinology.

[186]  Donald R. Campbell,et al.  Biphasic estrogen response on bovine adrenal medulla capillary endothelial cell adhesion, proliferation and tube formation , 1997, Molecular and Cellular Biochemistry.

[187]  L. Mariani,et al.  Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. , 1999, The American journal of pathology.

[188]  A. Arnold,et al.  Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. , 1995, The Journal of clinical investigation.

[189]  J. Martial,et al.  The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. , 1993, Endocrinology.

[190]  K. Kovacs,et al.  Vascular alterations in adenomas of human pituitary glands. An electron microscopic study. , 1973, Angiologica.

[191]  H. Sasano,et al.  Vascularity in human adrenal cortex. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[192]  I. Rooman,et al.  Effect of vascular endothelial growth factor on growth and differentiation of pancreatic ductal epithelium. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[193]  T. Thompson,et al.  Neuropeptides induce Mr 92,000 type IV collagenase (matrix metalloprotease-9) activity in human prostate cancer cell lines. , 1998, Cancer research.

[194]  J. Franklyn,et al.  Fibroblast growth factors 1 and 2 and fibroblast growth factor receptor 1 are elevated in thyroid hyperplasia. , 1998, The Journal of clinical endocrinology and metabolism.

[195]  B. Woda,et al.  Florid angiogenesis in mucosa surrounding an ileal carcinoid tumor expressing transforming growth factor-alpha. , 1997, The American journal of surgical pathology.

[196]  Y. Okada,et al.  Matrix metalloproteinase-9 (92 kDa gelatinase/type IV collagenase) from U937 monoblastoid cells: correlation with cellular invasion. , 1993, Journal of cell science.

[197]  Thomas N. Sato,et al.  Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF) , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[198]  K. Alitalo,et al.  Tie receptors: new modulators of angiogenic and lymphangiogenic responses , 2001, Nature Reviews Molecular Cell Biology.

[199]  E. van Marck,et al.  Correlation of the fractions of proliferating tumor and endothelial cells in breast and colorectal adenocarcinoma is independent of tumor histiotype and microvessel density. , 1997, Microvascular research.

[200]  Belghiti,et al.  Expression of vascular endothelial growth factor in digestive neuroendocrine tumours , 1998, Histopathology.

[201]  G. Martiny-Baron,et al.  Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. , 1996, Cancer research.

[202]  P. Chomczyński,et al.  Human growth hormone stimulates proliferation of human retinal microvascular endothelial cells in vitro. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[203]  M. Karkkainen,et al.  Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells , 1999, Molecular and Cellular Endocrinology.

[204]  D. Robie,et al.  The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults. , 2000, Thyroid : official journal of the American Thyroid Association.

[205]  A. L. Goodman,et al.  Thyroid angiogenesis: endotheliotropic chemoattractant activity from rat thyroid cells in culture. , 1987, Endocrinology.

[206]  Q. Sang,et al.  Complex role of matrix metalloproteinases in angiogenesis , 1998, Cell Research.

[207]  M. Longaker,et al.  Regulation of Vascular Endothelial Growth Factor Expression in Cultured Keratinocytes. , 1995, The Journal of Biological Chemistry.

[208]  A. Harris,et al.  Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[209]  M. Ivan,et al.  Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein , 2000, Nature Cell Biology.

[210]  A. Pozzi,et al.  Basic fibroblast growth factor in human pheochromocytoma: A biochemical and immunohistochemical study , 1993, International journal of cancer.

[211]  L. Jin,et al.  Analysis of homogeneous populations of anterior pituitary folliculostellate cells by laser capture microdissection and reverse transcription-polymerase chain reaction. , 2001, Endocrinology.

[212]  S. Melmed,et al.  Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. , 1999, The Journal of clinical endocrinology and metabolism.

[213]  M. Brandi A novel endothelial cell growth factor circulates in familial multiple endocrine neoplasia type 1. , 1990, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[214]  K. Alitalo,et al.  Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. , 1998, Science.

[215]  S. Iseki,et al.  Immunohistochemical localization of vascular endothelial growth factor in the endocrine glands of the rat. , 1998, Archives of histology and cytology.

[216]  S. Fukumoto,et al.  Peroxisome Proliferator-Activated Receptor-γ Agonists Increase Vascular Endothelial Growth Factor Expression in Human Vascular Smooth Muscle Cells , 2000 .

[217]  S. Kitano,et al.  Anti-tumor angiogenesis therapy using soluble receptors: enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor , 2002, Cancer Gene Therapy.

[218]  J. Folkman Clinical Applications of Research on Angiogenesis , 1995 .

[219]  S. Korem,et al.  Similar and divergent patterns in the regulation of matrix metalloproteinase-1 (MMP-1) and tissue inhibitor of MMP-1 gene expression in benign and malignant human thyroid cells. , 1999, The Journal of clinical endocrinology and metabolism.

[220]  J. Wass,et al.  Antiangiogenic effects of somatostatin analogues , 2002, Clinical endocrinology.

[221]  B. Scheithauer,et al.  Vasculature in nontumorous hypophyses, pituitary adenomas, and carcinomas: A quantitative morphologic study , 1995, Endocrine pathology.

[222]  Lars Holmgren,et al.  Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.

[223]  K. Alitalo,et al.  Endothelial Tie growth factor receptor provides antigenic marker for assessment of breast cancer angiogenesis. , 1996, British Journal of Cancer.

[224]  P. Carmeliet,et al.  New perspectives in the function of pituitary folliculo-stellate cells , 1990, Molecular and Cellular Endocrinology.

[225]  W Blumenfeld,et al.  Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. , 1993, The American journal of pathology.

[226]  L. Bresler*,et al.  Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. , 2001, The Journal of clinical endocrinology and metabolism.

[227]  S. Baylin,et al.  Roles of trk family neurotrophin receptors in medullary thyroid carcinoma development and progression. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[228]  A. Logan,et al.  Basic fibroblast growth factor: an autocrine mitogen of rat thyroid follicular cells? , 1992, Endocrinology.

[229]  M. Iruela-Arispe,et al.  Antiangiogenic Domains Shared by Thrombospondins and Metallospondins, a New Family of Angiogenic Inhibitors , 1999, Annals of the New York Academy of Sciences.

[230]  L. Liotta,et al.  Distribution of the 72-kd type IV collagenase in nonneoplastic and neoplastic thyroid tissue. , 1992, Human pathology.

[231]  L. Nelson,et al.  Human follicle fluid vascular endothelial growth factor concentrations are correlated with luteinization in spontaneously developing follicles. , 1998, Human reproduction.

[232]  M. Greaves,et al.  Leukocyte antigen CD34 is expressed by a subset of cultured endothelial cells and on endothelial abluminal microprocesses in the tumor stroma. , 1990, Laboratory investigation; a journal of technical methods and pathology.

[233]  Steven A. Stacker,et al.  VEGF-D promotes the metastatic spread of tumor cells via the lymphatics , 2001, Nature Medicine.

[234]  H. Esumi,et al.  Regulation of vascular endothelial growth factor expression by insulin‐like growth factor‐I in endometrial adenocarcinoma cells , 2000, International journal of cancer.

[235]  W. Risau,et al.  Mechanisms of angiogenesis , 1997, Nature.

[236]  G. Semenza,et al.  A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation , 1992, Molecular and cellular biology.

[237]  K. Kairemo,et al.  Inhibition of malignant angiogenesis. , 1997, Cancer treatment reviews.

[238]  N. Palanisamy,et al.  Novel chromosomal abnormalities identified by comparative genomic hybridization in parathyroid adenomas. , 1998, The Journal of clinical endocrinology and metabolism.

[239]  R. Tuan,et al.  Expression of Angiogenic Growth Factors in Paragangliomas , 2000, The Laryngoscope.

[240]  M. Shibuya Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. , 2001, Cell structure and function.

[241]  G. Bechtner,et al.  Release of an endothelial cell growth factor from cultured porcine thyroid follicles. , 1989, Molecular endocrinology.

[242]  K. Suzuki,et al.  Matrix metalloproteinases as insulin-like growth factor binding protein-degrading proteinases. , 1995, Progress in growth factor research.

[243]  S. Kumar,et al.  A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues , 1993, International journal of cancer.

[244]  H. Kihara,et al.  Pituitary folliculo-stellate cells immunostained with S-100 protein antiserum in postnatal, castrated and thyroidectomized rats , 2004, Cell and Tissue Research.

[245]  R. Coffey,et al.  Human carcinoid cell production of paracrine growth factors that can stimulate fibroblast and endothelial cell growth. , 1991, Cancer research.

[246]  Seppo Ylä-Herttuala,et al.  Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3 , 2001, Nature Medicine.

[247]  G. Semenza HIF-1 and mechanisms of hypoxia sensing. , 2001, Current opinion in cell biology.

[248]  P. Comoglio,et al.  Hepatocyte growth factor (HGF) stimulates tumour invasiveness in papillary carcinoma of the thyroid , 1999, The Journal of pathology.

[249]  J. Tímár,et al.  Multiple Roles for Platelet GPIIb/IIIa and αvβ3 Integrins in Tumor Growth, Angiogenesis, and Metastasis , 2002 .

[250]  D. Birnbaum,et al.  VEGFc and VEGFR3 expression in human thyroid pathologies , 2000, International journal of cancer.

[251]  F. Trimarchi,et al.  Expression of the hepatocyte growth factor and c-met in normal thyroid, non-neoplastic, and neoplastic nodules. , 1998, Thyroid : official journal of the American Thyroid Association.

[252]  C. Powers,et al.  Fibroblast growth factors, their receptors and signaling. , 2000, Endocrine-related cancer.

[253]  R. Hammer,et al.  The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. , 1998, Genes & development.

[254]  Karl H. Plate,et al.  From angiogenesis to lymphangiogenesis , 2001, Nature Medicine.

[255]  M. Brandi,et al.  Increased basic fibroblast growth factor in plasma from multiple endocrine neoplasia type 1: relation to pituitary tumor. , 1993, The Journal of clinical endocrinology and metabolism.

[256]  Y. Shiotani An electron microscopic study on stellate cells in the rabbit adenohypophysis under various endocrine conditions , 1980, Cell and Tissue Research.

[257]  A. Harris,et al.  Quantitation and prognostic value of breast cancer angiogenesis: Comparison of microvessel density, Chalkley count, and computer image analysis , 1995, The Journal of pathology.

[258]  M. Rechler,et al.  Proteolysis of Insulin-Like Growth Factor Binding Protein-3 in Serum from Pregnant, Non-Pregnant and Fetal Rats by Matrix Metalloproteinases and Serine Proteases , 1999, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[259]  K. Alitalo,et al.  A novel vascular endothelial growth factor, VEGF‐C, is a ligand for the Flt4 (VEGFR‐3) and KDR (VEGFR‐2) receptor tyrosine kinases. , 1996, The EMBO journal.

[260]  E. Woltering,et al.  Postreceptor signal transduction mechanisms involved in octreotide-induced inhibition of angiogenesis. , 1994, Surgery.

[261]  W. Scherbaum,et al.  mRNA levels of membrane-type 1 matrix metalloproteinase (MT1-MMP), MMP-2, and MMP-9 and of their inhibitors TIMP-2 and TIMP-3 in normal thyrocytes and thyroid carcinoma cell lines. , 1998, Thyroid : official journal of the American Thyroid Association.

[262]  J. Silverlight,et al.  BASIC FIBROBLAST GROWTH FACTOR IN HUMAN PITUITARY TUMOURS , 1990, Clinical endocrinology.

[263]  D. Hanahan,et al.  Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. , 1995, Molecular endocrinology.

[264]  L. Liotta,et al.  Extracellular matrix 6: Role of matrix metalloproteinases in tumor invasion and metastasis , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[265]  S. Melmed,et al.  Human pituitary tumor-transforming gene induces angiogenesis. , 2001, The Journal of clinical endocrinology and metabolism.

[266]  G. Stancel,et al.  Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. , 2000, Cancer research.

[267]  X. Bertagna,et al.  Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. , 1994, The Journal of clinical endocrinology and metabolism.

[268]  S. Fox,et al.  Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. , 1996, European journal of cancer.

[269]  Janice A. Nagy,et al.  The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor , 2001, Nature Medicine.

[270]  Leonard,et al.  Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. , 1997, Cancer research.

[271]  M. Shibuya,et al.  Expression of vascular endothelial growth factor (VEGF) in human thyroid neoplasms. , 1999, Human pathology.

[272]  A. Ferrando,et al.  Structure and expression in breast tumors of human TIMP-3, a new member of the metalloproteinase inhibitor family. , 1994, Cancer research.

[273]  D. Mukhopadhyay,et al.  High cell density induces vascular endothelial growth factor expression via protein tyrosine phosphorylation. , 1998, Gene expression.

[274]  Kenneth J. Hillan,et al.  Vascular endothelial growth factor is essential for corpus luteum angiogenesis , 1998, Nature Medicine.

[275]  K. Kołomecki,et al.  Vascular endothelial growth factor and basic fibroblast growth factor evaluation in blood serum of patients with hormonally active and inactive adrenal gland tumours. , 2000, Cytobios.

[276]  F. Peillon,et al.  Specific alterations of the basement membrane and stroma antigens in Human pituitary tumours in comparison with the normal anterior pituitary. An immunocytochemical study , 2005, Virchows Archiv.

[277]  C. Lotfi,et al.  Control of the adrenocortical cell cycle: interaction between FGF2 and ACTH. , 1999, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[278]  N. Ferrara,et al.  Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. , 1989, Biochemical and biophysical research communications.

[279]  H. Wieland,et al.  Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids. , 1997, American journal of respiratory cell and molecular biology.

[280]  N. Simionescu,et al.  Structural aspects of the permeability of the microvascular endothelium. , 1979, Acta physiologica Scandinavica. Supplementum.

[281]  T. Obara,et al.  Insulin-like growth factor I receptors and insulin-like growth factor-binding proteins in human parathyroid tumors , 1994, World Journal of Surgery.

[282]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[283]  B. Scheithauer,et al.  Microvessel density in pituitary adenomas and carcinomas , 2001, Virchows Archiv.

[284]  H. Sugimura,et al.  Antitumor Effect of a Neutralizing Antibody to Vascular Endothelial Growth Factor on Liver Metastasis of Endocrine Neoplasm , 1998, Japanese journal of cancer research : Gann.

[285]  K. Alitalo,et al.  Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[286]  J. Folkman,et al.  TUMOR DORMANCY IN VIVO BY PREVENTION OF NEOVASCULARIZATION , 1972, The Journal of experimental medicine.

[287]  D. Benezra Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. , 1997, Investigative ophthalmology & visual science.

[288]  G. Popa A Portal Circulation from the Pituitary to the Hypothalamic Region. , 1930, Journal of anatomy.

[289]  V. Dixit,et al.  Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. , 1994, The American journal of pathology.

[290]  G. Fontanini,et al.  Microvessel count: an indicator of poor outcome in medullary thyroid carcinoma but not in other types of thyroid carcinoma. , 1996, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[291]  D. Robertson,et al.  Matrix metalloproteinases 2 and 9 in canine rheumatoid arthritis , 1998, Veterinary Record.

[292]  R Bicknell,et al.  Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. , 1993, Cancer research.

[293]  R. Weiner,et al.  Inhibition of estrogen-induced anterior pituitary enlargement and arteriogenesis by bromocriptine in Fischer 344 rats. , 1987, Endocrinology.

[294]  J. Bertherat,et al.  Pathogenesis of adrenocortical incidentalomas and genetic syndromes associated with adrenocortical neoplasms. , 2000, Endocrinology and metabolism clinics of North America.

[295]  T. Porter,et al.  Stimulation of lactotrope differentiation in vitro by fibroblast growth factor. , 1994, Endocrinology.

[296]  M. Shibuya,et al.  Increase of vascular endothelial growth factor mRNA expression by 1,25‐dihydroxyvitamin D3 in human osteoblast‐like cells , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[297]  J. Chudek,et al.  Genetic abnormalities in parathyroid nodules of uremic patients. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[298]  B. Scheithauer,et al.  Localization of vascular endothelial growth factor in nontumorous human pituitaries , 1999, Endocrine pathology.

[299]  H. Sugihara,et al.  Fibroblast growth factor-2 free from extracellular matrix is increased in papillary thyroid carcinomas and Graves' thyroids. , 1998, Thyroid : official journal of the American Thyroid Association.

[300]  K. W. Kim,et al.  Identification of angiogenic properties of insulin-like growth factor II in in vitro angiogenesis models , 2000, British Journal of Cancer.

[301]  H. Yamaguchi,et al.  S100 protein in folliculostellate cells of the rat pituitary anterior lobe , 1980, Brain Research.

[302]  S. Dobbs,et al.  Angiogenesis is associated with vascular endothelial growth factor expression in cervical intraepithelial neoplasia. , 1997, British Journal of Cancer.

[303]  L. Ding,et al.  Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. , 1999, Cancer research.

[304]  N. Usuda,et al.  Therapeutic efficacy of the angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470) for human anaplastic thyroid carcinoma in nude mice. , 1997, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[305]  J. Gogusev,et al.  De novo expression of transforming growth factor-alpha in parathyroid gland tissue of patients with primary or secondary uraemic hyperparathyroidism. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[306]  S. Asa,et al.  Heterogenous in vivo and in vitro expression of basic fibroblast growth factor by human pituitary adenomas. , 1995, The Journal of clinical endocrinology and metabolism.

[307]  C. Readhead,et al.  Pituitary-directed leukemia inhibitory factor transgene forms Rathke's cleft cysts and impairs adult pituitary function. A model for human pituitary Rathke's cysts. , 1997, The Journal of clinical investigation.

[308]  M. Feinmesser,et al.  Angiogenesis in follicular tumors of the thyroid , 1996, Journal of surgical oncology.

[309]  H. Namba,et al.  Inhibition of angiogenesis and tumorigenesis, and induction of dormancy by p53 in a p53-null thyroid carcinoma cell line in vivo. , 2000, Anticancer research.

[310]  M. Beato,et al.  Inducible regulatory elements in the human cyclin D1 promoter. , 1994, Oncogene.

[311]  N. Hashimoto,et al.  Immunohistochemical study for basic fibroblast growth factor and fibroblast growth factor receptor I in pituitary adenomas , 1994, Neuroscience Letters.

[312]  H. Höfler,et al.  Immunohistochemistry of folliculo-stellate cells in normal human adenohypophyses and in pituitary adenomas , 2004, Acta Neuropathologica.

[313]  G. Stancel,et al.  Progestin regulation of vascular endothelial growth factor in human breast cancer cells. , 1998, Cancer research.

[314]  M. Neeman,et al.  Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes , 1995, Molecular and cellular biology.

[315]  A. Arnold,et al.  Coding sequence of the overexpressed transcript of the putative oncogene PRAD1/cyclin D1 in two primary human tumors. , 1993, Oncogene.

[316]  H. Jabbour,et al.  Pattern and localisation of expression of vascular endothelial growth factor and its receptor flt-1 in the ovine pituitary gland: expression is independent of hypothalamic control , 1997, Molecular and Cellular Endocrinology.

[317]  T. Obara,et al.  Vascular endothelial growth factor-C gene expression in papillary and follicular thyroid carcinomas. , 1999, Surgery.

[318]  F. Trimarchi,et al.  Loss of heterozygosity of the long arm of chromosome 7 in follicular and anaplastic thyroid cancer, but not in papillary thyroid cancer. , 1999, The Journal of clinical endocrinology and metabolism.

[319]  S. Melmed,et al.  Isolation and characterization of a pituitary tumor-transforming gene (PTTG). , 1997, Molecular endocrinology.

[320]  D. Millhorn,et al.  Hypoxia Induces Phosphorylation of the Cyclic AMP Response Element-binding Protein by a Novel Signaling Mechanism* , 1998, The Journal of Biological Chemistry.

[321]  B. Scheithauer,et al.  Immunolocalization of vascular endothelial growth factor in the GH3 cell line , 2000, Cell and Tissue Research.

[322]  A. Giatromanolaki,et al.  Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[323]  K. Kameyama Expression of MMP-1 in the capsule of thyroid cancer--relationship with invasiveness. , 1996, Pathology, research and practice.

[324]  J. Folkman What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[325]  D. Ribatti,et al.  Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. , 1999, Blood.

[326]  K. Horgan,et al.  Effect of Growth Factors on Growth of Bovine Parathyroid Cells in Serum-Free Medium , 1996, World Journal of Surgery.

[327]  M. Noguchi,et al.  Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas. , 1999, Cancer research.

[328]  G. Mashour,et al.  Aberrant cutaneous expression of the angiogenic factor midkine is associated with neurofibromatosis type-1. , 1999, The Journal of investigative dermatology.

[329]  W. Kaelin,et al.  Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[330]  S. Fox,et al.  Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenes , 1997, Cancer research.

[331]  C. Martínez-A,et al.  Insulin-like growth factor I-triggered cell migration and invasion are mediated by matrix metalloproteinase-9. , 1999, Endocrinology.

[332]  R. Luna,et al.  Cell cycle regulated expression and phosphorylation of hpttg proto-oncogene product , 2000, Oncogene.

[333]  J. Folkman Editorial: Is Tissue Mass Regulated by Vascular Endothelial Cells? Prostate as the First Evidence. , 1998, Endocrinology.

[334]  P. Kelly,et al.  The prolactin gene is expressed in the hypothalamic-neurohypophyseal system and the protein is processed into a 14-kDa fragment with activity like 16-kDa prolactin. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[335]  C. Larsson,et al.  Gelatinase A and Membrane-type 1 Matrix Metalloproteinase mRNA: Expressed in Adrenocortical Cancers but Not in Adenomas , 1999, World Journal of Surgery.

[336]  M. Tachibana,et al.  Tumor vascularity predicts recurrence in differentiated thyroid carcinoma. , 1998, American journal of surgery.

[337]  K. Alitalo,et al.  Vascular growth factors and lymphangiogenesis. , 2002, Physiological reviews.

[338]  S M Schwartz,et al.  Angiogenesis in human coronary atherosclerotic plaques. , 1994, The American journal of pathology.

[339]  M. Capdevielle,et al.  Angiogenic activity of anterior pituitary tissue and growth hormone on the chick embryo chorio-allantoic membrane: a novel action of GH. , 1995, Life sciences.

[340]  Lois E. H. Smith,et al.  Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor , 1999, Nature Medicine.

[341]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[342]  K. Yamazaki,et al.  Stimulation by thyroid-stimulating hormone and Grave's immunoglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and flt mRNA expression in the rat thyroid in vivo. , 1995, The Journal of clinical investigation.

[343]  J. Rosai,et al.  Localization of factor VIII-related antigen in vascular endothelial cells using an immunoperoxidase method. , 1980, The American journal of surgical pathology.

[344]  A. Giatromanolaki,et al.  Assessment of vascular maturation in non-small cell lung cancer using a novel basement membrane component, LH39: correlation with p53 and angiogenic factor expression. , 1999, Cancer research.

[345]  W. Carter,et al.  Stimulation of angiogenesis by canine parathyroid tissue. , 1996, Surgery.

[346]  R. Weiner,et al.  A specific, high affinity, saturable binding site for the 16-kilodalton fragment of prolactin on capillary endothelial cells. , 1992, Endocrinology.

[347]  A. Irrthum,et al.  A gene for inherited cutaneous venous anomalies ("glomangiomas") localizes to chromosome 1p21-22. , 1999, American journal of human genetics.

[348]  A. Kossakowska,et al.  Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans. , 1996, British Journal of Cancer.

[349]  A. Miettinen,et al.  Ulex europaeus I lectin as a marker for vascular endothelium in human tissues. , 1982, Laboratory investigation; a journal of technical methods and pathology.

[350]  T. L. Moser,et al.  Angiostatin binds ATP synthase on the surface of human endothelial cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[351]  A. Bergh,et al.  Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. , 1998, Endocrinology.

[352]  K. Dameron,et al.  Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. , 1994, Science.

[353]  R. Khokha,et al.  Insulin-like Growth Factor II Signaling in Neoplastic Proliferation Is Blocked by Transgenic Expression of the Metalloproteinase Inhibitor Timp-1 , 1999, The Journal of cell biology.

[354]  R. Deitch The start of a long debate on the Warnock report. , 1984, Lancet.

[355]  D. Ribatti,et al.  Anti-angiogenic activity of the purine analog 6-thioguanine , 2002, Leukemia.

[356]  J. Folkman,et al.  Quantitation of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane. , 1994, Microvascular research.

[357]  M. Stack,et al.  The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin , 1997 .

[358]  N. Ferrara,et al.  Corticotropin regulates vascular endothelial growth factor expression in human fetal adrenal cortical cells. , 1998, The Journal of clinical endocrinology and metabolism.

[359]  Janet Rossant,et al.  Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice , 1995, Nature.

[360]  J. Schlessinger Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[361]  P. Cohen,et al.  Leukotriene D4 induces MMP-1, which functions as an IGFBP protease in human airway smooth muscle cells. , 1996, The American journal of physiology.

[362]  F. Sarkar,et al.  Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. , 1995, The Journal of clinical investigation.

[363]  L. Liotta,et al.  Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation , 1991, Cell.

[364]  A. Harvey,et al.  Intermittent administration of parathyroid hormone (1‐34) stimulates matrix metalloproteinase‐9 (MMP‐9) expression in rat long bone , 1998, Journal of cellular biochemistry.

[365]  D. Donner,et al.  Induction of Vascular Endothelial Growth Factor by Insulin-like Growth Factor 1 in Colorectal Carcinoma* , 1996, The Journal of Biological Chemistry.

[366]  T. Yamamoto,et al.  Therapeutic usefulness of wild-type p53 gene introduction in a p53-null anaplastic thyroid carcinoma cell line. , 1998, The Journal of clinical endocrinology and metabolism.

[367]  A. Ullrich,et al.  Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. , 1996, Cancer research.

[368]  B. J. Harrison,et al.  Fibroblast Growth Factors and Their Receptors in Parathyroid Disease , 1998, World Journal of Surgery.

[369]  A. Arnold,et al.  Loss of chromosome arm 9p DNA and analysis of the p16 and p15 cyclin-dependent kinase inhibitor genes in human parathyroid adenomas. , 1996, The Journal of clinical endocrinology and metabolism.

[370]  M. Gerritsen,et al.  Peroxisome Proliferator-activated Receptor γ Ligands Are Potent Inhibitors of Angiogenesis in Vitro and in Vivo * , 1999, The Journal of Biological Chemistry.

[371]  K. Usadel,et al.  T lymphocytes, CD68-positive cells and vascularisation in thyroid carcinomas , 2005, Journal of Cancer Research and Clinical Oncology.

[372]  A. Harris,et al.  Angiogenesis in pituitary adenomas - relationship to endocrine function, treatment and outcome. , 2000, Journal of Endocrinology.

[373]  B. Olffson Vascular endothelial grouth facter B, a novel growth facter for endothelial cells , 1996 .

[374]  J. Widdicombe,et al.  Transport epithelial characteristics of cultured bovine pituitary follicular cells. , 1987, The American journal of physiology.

[375]  F Pozza,et al.  Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. , 1992, Journal of the National Cancer Institute.

[376]  J. Fiddes,et al.  Basic fibroblast growth factor: production and growth stimulation in cultured adrenal cortex cells. , 1987, Endocrinology.

[377]  U. Moll,et al.  Mr 92,000 Type IV Collagenase Is Increased in Plasma of Patients with Colon Cancer and Breast Cancer , 1993 .

[378]  W. Cavenee,et al.  Expression of vascular endothelial growth factor in human brain tumors , 1998, Acta Neuropathologica.

[379]  N. Harris,et al.  PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[380]  S. Melmed,et al.  Human and murine pituitary expression of leukemia inhibitory factor. Novel intrapituitary regulation of adrenocorticotropin hormone synthesis and secretion. , 1995, The Journal of clinical investigation.

[381]  N. Ferrara,et al.  The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. , 1991, Endocrinology.

[382]  T. Terada,et al.  An immunohistochemical study of tumour vessels in metastatic liver cancers and the surrounding liver tissue , 1996, Histopathology.

[383]  P. Esbrit,et al.  C-terminal parathyroid hormone-related protein increases vascular endothelial growth factor in human osteoblastic cells. , 2000, Journal of the American Society of Nephrology : JASN.

[384]  N. Ferrara,et al.  Vascular endothelial growth factor and the regulation of angiogenesis. , 2000, Recent progress in hormone research.

[385]  Y. Chung,et al.  Tumor angiogenesis as a predictor of recurrence in gastric carcinoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[386]  Bao Q. Pham,et al.  Curcuminoids Inhibit the Angiogenic Response Stimulated by Fibroblast Growth Factor-2, Including Expression of Matrix Metalloproteinase Gelatinase B* , 2000, The Journal of Biological Chemistry.

[387]  Lois E. H. Smith,et al.  Essential role of growth hormone in ischemia-induced retinal neovascularization. , 1997, Science.

[388]  E. Laws,et al.  The primary angiographic findings in pituitary adenomas. , 1974, Radiology.

[389]  Q. Duh,et al.  Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. , 1997, The Journal of clinical endocrinology and metabolism.

[390]  W T Yuh,et al.  Sequential MR enhancement pattern in normal pituitary gland and in pituitary adenoma. , 1994, AJNR. American journal of neuroradiology.

[391]  S. Tsuchiya,et al.  Expression of basic fibroblast growth factor in hyperplastic parathyroid glands from patients with multiple endocrine neoplasia type I , 1994, World Journal of Surgery.

[392]  P. Brodt,et al.  Regulation of the Mr 72,000 type IV collagenase by the type I insulin-like growth factor receptor. , 1998, Cancer research.

[393]  P. Sharp The role of growth factors in the development of diabetic retinopathy. , 1995, Metabolism: clinical and experimental.

[394]  S. Fox,et al.  Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39 , 2000, British Journal of Cancer.

[395]  M. Stack,et al.  Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. , 1996, Cancer research.

[396]  J. Rossant,et al.  Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium , 1995, Nature.

[397]  T. Nakamura,et al.  Hepatocyte growth factor increases expression of vascular endothelial growth factor and plasminogen activator inhibitor-1 in human keratinocytes and the vascular endothelial growth factor receptor flk-1 in human endothelial cells. , 1999, Laboratory investigation; a journal of technical methods and pathology.